CTI BioPharma Investor Relations Material
Latest events
Q4 2022
CTI BioPharma
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from CTI BioPharma Corp
Access all reports
CTI BioPharma Corp. is a biopharmaceutical company focused on the development and commercialization of novel therapies for blood-related cancers. The company’s lead product is designed to treat patients with rare blood cancers, such as myelofibrosis. The company is headquartered in Seattle, Washington, and its shares are listed on the NASDAQ.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
CTIC
Country
🇺🇸 United States